Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-08
DOI
10.1038/srep35533
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
- (2016) John K. Lee et al. CANCER CELL
- A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
- (2016) Daniel Dauch et al. NATURE MEDICINE
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype
- (2016) Feimeng Zheng et al. Nature Communications
- p53, ROS and senescence in the control of aging
- (2016) Arnaud Vigneron et al. Aging-US
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance
- (2014) F.-M. Zheng et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation
- (2014) Xiao-Na Pan et al. PLoS One
- Kinase Drug Discovery – What’s Next in the Field?
- (2013) Philip Cohen et al. ACS Chemical Biology
- Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
- (2013) X. Shi et al. CLINICAL CANCER RESEARCH
- Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2013) Kevin R. Kelly et al. INVESTIGATIONAL NEW DRUGS
- Inhibition of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora Inhibitors by Suppression of Glycolytic Metabolism
- (2013) L.-L. Liu et al. MOLECULAR CANCER RESEARCH
- Dual regulation of Myc by Abl
- (2013) V J Sanchez-Arévalo Lobo et al. ONCOGENE
- Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells
- (2012) Y. Wu et al. CLINICAL CANCER RESEARCH
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
- (2012) B. Valsasina et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model
- (2011) Hongfeng Yuan et al. CARCINOGENESIS
- Upregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidy
- (2011) Donald McCrann et al. CELL CYCLE
- Molecular Pathways: BCR-ABL
- (2011) D. Cilloni et al. CLINICAL CANCER RESEARCH
- Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway
- (2011) Hee-Jin Kim et al. FEBS LETTERS
- Tumorigenic polyploid cells contain elevated ROS and ARE selectively targeted by antioxidant treatment
- (2011) Meejeon Roh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Aurora-A Is Essential for the Tumorigenic Capacity and Chemoresistance of Colorectal Cancer Stem Cells
- (2010) Patrizia Cammareri et al. CANCER RESEARCH
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo
- (2010) J. J. Huck et al. MOLECULAR CANCER RESEARCH
- Second-Generation BCR-ABL Kinase Inhibitors in CML
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Paradoxical suppression of cellular senescence by p53
- (2010) Z. N. Demidenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
- (2009) Nicholas J. Donato et al. BIOCHEMICAL PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:In vitroandin vivostudies
- (2008) Daigo Akahane et al. CANCER SCIENCE
- Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
- (2008) W. Fiskus et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now